Summit Therapeutics plc (SMMT): Price and Financial Metrics


Summit Therapeutics plc (SMMT): $1.24

0.45 (+57.67%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SMMT POWR Grades

  • SMMT scores best on the Sentiment dimension, with a Sentiment rank ahead of 86.55% of US stocks.
  • SMMT's strongest trending metric is Growth; it's been moving down over the last 73 days.
  • SMMT's current lowest rank is in the Momentum metric (where it is better than 4.49% of US stocks).

SMMT Stock Summary

  • With a price/sales ratio of 165.31, SUMMIT THERAPEUTICS INC has a higher such ratio than 98.24% of stocks in our set.
  • As for revenue growth, note that SMMT's revenue has grown -45.15% over the past 12 months; that beats the revenue growth of merely 4.37% of US companies in our set.
  • In terms of volatility of its share price, SMMT is more volatile than 92.02% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to SUMMIT THERAPEUTICS INC are NTLA, FATE, RLAY, IGMS, and XNCR.
  • SMMT's SEC filings can be seen here. And to visit SUMMIT THERAPEUTICS INC's official web site, go to www.summitplc.com.

SMMT Valuation Summary

  • SMMT's price/sales ratio is 164.2; this is 8110% higher than that of the median Healthcare stock.
  • Over the past 94 months, SMMT's EV/EBIT ratio has gone up 6.1.

Below are key valuation metrics over time for SMMT.

Stock Date P/S P/B P/E EV/EBIT
SMMT 2022-12-02 164.2 1.2 -1.8 -0.5
SMMT 2022-12-01 143.2 1.0 -1.6 -0.2
SMMT 2022-11-30 168.5 1.2 -1.9 -0.5
SMMT 2022-11-29 187.4 1.3 -2.1 -0.7
SMMT 2022-11-28 197.9 1.4 -2.2 -0.8
SMMT 2022-11-25 194.4 1.4 -2.1 -0.8

SMMT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SMMT has a Quality Grade of D, ranking ahead of 7.27% of graded US stocks.
  • SMMT's asset turnover comes in at 0.006 -- ranking 406th of 682 Pharmaceutical Products stocks.
  • EDIT, SAGE, and SVRA are the stocks whose asset turnover ratios are most correlated with SMMT.

The table below shows SMMT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.006 1 -10.188
2020-12-31 0.009 1 -12.994
2019-10-31 -0.197 1 -4.153
2019-07-31 -0.198 1 -4.482
2019-04-30 0.605 1 1.189
2019-01-31 0.604 1 0.877

SMMT Price Target

For more insight on analysts targets of SMMT, see our SMMT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.50 Average Broker Recommendation 1.5 (Moderate Buy)

SMMT Stock Price Chart Interactive Chart >

Price chart for SMMT

SMMT Price/Volume Stats

Current price $1.24 52-week high $5.30
Prev. close $0.79 52-week low $0.66
Day low $1.21 Volume 28,186,154
Day high $1.44 Avg. volume 759,513
50-day MA $1.06 Dividend yield N/A
200-day MA $1.43 Market Cap 249.18M

Summit Therapeutics plc (SMMT) Company Bio


Summit Therapeutics plc operates as a biopharmaceutical company primarily in the United Kingdom and the Unites States. It focuses on the discovery, development, and commercialization of novel medicines to treat the Duchenne Muscular Dystrophy (DMD), a fatal muscle wasting disease; and infections caused by Clostridium difficile bacteria (CDI). The company was founded in 2003 and is based in Abingdon, England.


SMMT Latest News Stream


Event/Time News Detail
Loading, please wait...

SMMT Latest Social Stream


Loading social stream, please wait...

View Full SMMT Social Stream

Latest SMMT News From Around the Web

Below are the latest news stories about SUMMIT THERAPEUTICS INC that investors may wish to consider to help them evaluate SMMT as an investment opportunity.

Summit Therapeutics Appoints Experienced Clinical Leader Dr. Alessandra Cesano to its Board of Directors

Menlo Park, California, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Dr. Alessandra Cesano, MD, PhD, has been appointed to its Board of Directors, effective immediately. “Dr. Cesano compliments our Board of Directors with her decades of extensive experience in the global clinical development of oncology drugs,” stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. “As we intend to expand our p

Yahoo | November 17, 2022

Summit Therapeutics Third Quarter 2022 Earnings: US$0.14 loss per share (vs US$0.20 loss in 3Q 2021)

Summit Therapeutics ( NASDAQ:SMMT ) Third Quarter 2022 Results Key Financial Results Net loss: US$21.4m (loss widened...

Yahoo | November 12, 2022

Summit Therapeutics Inc. Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2022

Menlo Park, California, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the third quarter and nine months ended September 30, 2022. Financial Highlights Aggregate cash, accounts receivable, and tax credits receivable on September 30, 2022 totaled $138.4 million as compared to $89.0 million on December 31, 2021. Our cash balance on September 30, 2022

Yahoo | November 9, 2022

Summit Therapeutics Presents Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022

Ridinilazole resulted in a 53% relative risk reduction in recurrence of C. difficile infection compared to treatment with vancomycin Ridinilazole preserved the gut microbiome compared to vancomycin: both in composition and diversity of the microbiome community Ri-CoDIFy represents the largest and most comprehensive CDI assessment of the gut microbiome to date from over 600 CDI patients Ridinilazole’s features are consistent with the principles of good antibiotic stewardship Menlo Park, Californi

Yahoo | October 20, 2022

Shareholders in Summit Therapeutics (NASDAQ:SMMT) are in the red if they invested five years ago

While it may not be enough for some shareholders, we think it is good to see the Summit Therapeutics Inc. ( NASDAQ:SMMT...

Yahoo | October 18, 2022

Read More 'SMMT' Stories Here

SMMT Price Returns

1-mo 20.39%
3-mo 8.77%
6-mo 16.98%
1-year -75.35%
3-year -19.48%
5-year -89.18%
YTD -53.90%
2021 -42.77%
2020 193.75%
2019 39.13%
2018 -89.62%
2017 29.44%

Continue Researching SMMT

Here are a few links from around the web to help you further your research on Summit Therapeutics plc's stock as an investment opportunity:

Summit Therapeutics plc (SMMT) Stock Price | Nasdaq
Summit Therapeutics plc (SMMT) Stock Quote, History and News - Yahoo Finance
Summit Therapeutics plc (SMMT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7711 seconds.